Omalizumab induced Takotsubo syndrome: case report

BACKGROUND: Omalizumab is a humanized monoclonal anti-immunoglobulin E antibody, approved for the treatment of spontaneous chronic urticaria, with high efficacy and an excellent safety profile. Although its adverse effects are rare, allergic reactions and cardiovascular events were previously descri...

Descripción completa

Detalles Bibliográficos
Autores principales: Aguiar-Ricardo, Inês, Nunes-Ferreira, Afonso, Roda, Ângela, Bras-Rosario, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439385/
https://www.ncbi.nlm.nih.gov/pubmed/31020231
http://dx.doi.org/10.1093/ehjcr/yty155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439385/
https://www.ncbi.nlm.nih.gov/pubmed/31020231
http://dx.doi.org/10.1093/ehjcr/yty155

Ejemplares similares